Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hack

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
The Oncologist|February 18, 2017
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal CancerJohanna C Bendell, Howard Hochster, Lowell L Hart, et al.
American Heart Journal|April 23, 2023
Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction - A post hoc analysis of the cel-02 phase IIa studySem A O F Rikken, Willem L Bor, Abi Selvarajah, et al.
Heart and Vessels|June 28, 2020
Risk factors for permanent pacemaker implantation in patients receiving a balloon-expandable transcatheter aortic valve prosthesisMichal Droppa, Tanja K Rudolph, Jan Baan, et al.
The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2024
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 TrialTeresa Macarulla, Zhenggang Ren, Hong Jae Chon, et al.
The New England Journal of Medicine|September 30, 2014
Combined vemurafenib and cobimetinib in BRAF-mutated melanomaJames Larkin, Paolo A Ascierto, Brigitte Dréno, et al.
Cell Reports. Medicine|November 29, 2025
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapyYulei Wang, Yinghui Guan, Alexander R Abbas, et al.
Lancet (London, England)|October 23, 2023
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Minshan Chen, Ann-Lii Cheng, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
The Oncologist|February 18, 2017
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal CancerJohanna C Bendell, Howard Hochster, Lowell L Hart, et al.
American Heart Journal|April 23, 2023
Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction - A post hoc analysis of the cel-02 phase IIa studySem A O F Rikken, Willem L Bor, Abi Selvarajah, et al.
Heart and Vessels|June 28, 2020
Risk factors for permanent pacemaker implantation in patients receiving a balloon-expandable transcatheter aortic valve prosthesisMichal Droppa, Tanja K Rudolph, Jan Baan, et al.
The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2024
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 TrialTeresa Macarulla, Zhenggang Ren, Hong Jae Chon, et al.
The New England Journal of Medicine|September 30, 2014
Combined vemurafenib and cobimetinib in BRAF-mutated melanomaJames Larkin, Paolo A Ascierto, Brigitte Dréno, et al.
Cell Reports. Medicine|November 29, 2025
Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapyYulei Wang, Yinghui Guan, Alexander R Abbas, et al.
Lancet (London, England)|October 23, 2023
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trialShukui Qin, Minshan Chen, Ann-Lii Cheng, et al.
Pageof 4